- Home
- PMT vs DVAX Comparison
PMT vs DVAX Comparison
Compare PMT & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMT
- DVAX
- Stock Information
- Founded
- PMT 2009
- DVAX 1996
- Country
- PMT United States
- DVAX United States
- Employees
- PMT N/A
- DVAX N/A
- Industry
- PMT Real Estate Investment Trusts
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- PMT Real Estate
- DVAX Health Care
- Exchange
- PMT Nasdaq
- DVAX Nasdaq
- Market Cap
- PMT 1.1B
- DVAX 1.2B
- IPO Year
- PMT 2009
- DVAX 2004
- Fundamental
- Price
- PMT $11.84
- DVAX $10.06
- Analyst Decision
- PMT Hold
- DVAX Buy
- Analyst Count
- PMT 6
- DVAX 4
- Target Price
- PMT $14.20
- DVAX $26.50
- AVG Volume (30 Days)
- PMT 859.5K
- DVAX 1.3M
- Earning Date
- PMT 10-21-2025
- DVAX 11-06-2025
- Dividend Yield
- PMT 13.65%
- DVAX N/A
- EPS Growth
- PMT N/A
- DVAX N/A
- EPS
- PMT 0.72
- DVAX N/A
- Revenue
- PMT $614,826,000.00
- DVAX $316,268,000.00
- Revenue This Year
- PMT N/A
- DVAX $23.23
- Revenue Next Year
- PMT $27.87
- DVAX $16.57
- P/E Ratio
- PMT $16.29
- DVAX N/A
- Revenue Growth
- PMT 13.07
- DVAX 26.66
- 52 Week Low
- PMT $11.60
- DVAX $9.20
- 52 Week High
- PMT $14.93
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- PMT 42.67
- DVAX 50.78
- Support Level
- PMT $11.60
- DVAX $9.71
- Resistance Level
- PMT $12.11
- DVAX $10.12
- Average True Range (ATR)
- PMT 0.25
- DVAX 0.25
- MACD
- PMT -0.06
- DVAX 0.01
- Stochastic Oscillator
- PMT 21.03
- DVAX 53.08
About PMT PennyMac Mortgage Investment Trust of Beneficial Interest
PennyMac Mortgage Investment Trust is a specialty finance company that invests primarily in residential mortgage loans and mortgage-related assets. The company's operations include activities such as the production and servicing of financial securities based on residential loans and the pooling and reselling of high-credit-quality mortgages. The company operates through three segments: correspondent production, credit-sensitive strategies, interest-rate-sensitive strategies. The Credit sensitive strategies segment generates income via investments in CRT arrangements, subordinate MBS, distressed loans, and real estate.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.